Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 447 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IV Fluids Clear all
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
26
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Not applicable Interventional Results available

Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery

NCT01866657
View directory record Official record
Conditions
Hypoxia
Interventions
Vasoconstrictor Agents, Head/neck repositioning, Increase ETCO2, IV fluid bolus, Additional anesthesia, RBC transfusion, Increase FiO2
Drug · Other · Biological
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
65 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

NCT00579501
View directory record Official record
Conditions
Liposarcoma,Myxoid
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Coeur d'Alene, Idaho • Park Ridge, Illinois • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

NCT00101101
View directory record Official record
Conditions
Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, Autologous Tumor Cell-Based Vaccine, IL-2
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

NCT02167958
View directory record Official record
Conditions
Leukemia, MDS, Myelofibrosis, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF
Drug · Radiation · Other
Lead sponsor
Rafic Farah, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 20, 2026, 10:04 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Efficacy of Using Solum IV and BMC With GFC in TLIF

NCT03223701
View directory record Official record
Conditions
Degenerative Disc Disease, Isthmic-lytic Spondylolisthesis, Degenerative Spondylolisthesis, Spinal Stenosis
Interventions
Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion
Combination Product
Lead sponsor
Seton Healthcare Family
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 20, 2026, 10:04 PM EDT
Recruiting No phase listed Observational

SSVC-CI During CABG

NCT06645327
View directory record Official record
Conditions
Coronary Artery Bypass Grafting Surgery (CABG)
Interventions
a change in operating room table position, which will mimic an IV fluid bolus
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

NCT02525861
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency
Interventions
GLASSIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 20, 2026, 10:04 PM EDT
Not listed Not applicable Interventional

Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning

NCT06418022
View directory record Official record
Conditions
Shock, Fluid Overload, Cardiac Output, Low
Interventions
Trendelenburg positioning VTI
Device
Lead sponsor
Lenox Hill Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Trial Testing Buzzy Bee vs Vapocoolant During IV Placement

NCT06182631
View directory record Official record
Conditions
Intravenous Administration
Interventions
Buzzy Bee, Vapocoolent, Placebo
Device · Drug · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
6 Years to 18 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting

NCT01123837
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Intravenous fluid, D5LR or lactated ringers
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 1 Interventional

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

NCT05270057
View directory record Official record
Conditions
B-cell Lymphoma, Burkitt Lymphoma
Interventions
Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, Loncastuximab Tesirine 0.075 mg/kg by IV, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Dallas, Texas • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Rezafungin

NCT04117607
View directory record Official record
Conditions
Fungal Infection
Interventions
Placebo, Rezafungin
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

NCT02930044
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Early administration of subcutaneous insulin glargine dose, IV insulin infusion, IV fluid repletion
Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

NCT00431275
View directory record Official record
Conditions
Melanoma
Interventions
CP-675,206
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
8
States / cities
Scottsdale, Arizona • Aurora, Colorado • Aventura, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Early Phase 1 Interventional

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

NCT02338037
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Adult Brain, Primary Brain Tumor
Interventions
Therapeutic Conventional Surgery, Biopsy, Eribulin Mesylate, Microdialysis, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00137969
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Placebo, Prednisone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 2 Interventional

Trial Comparing Early Laparoscopic Enterolysis Versus Nonoperative Management for High-grade SBO

NCT02692638
View directory record Official record
Conditions
Small Bowel Obstruction
Interventions
Early laparoscopic enterolysis, nonoperative management
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

NCT03315104
View directory record Official record
Conditions
Influenza A H3N2, Influenza A H1N1
Interventions
FLU-IGIV, Placebo for FLU-IGIV
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor

NCT01942356
View directory record Official record
Conditions
Acute Cholecystitis, Chronic Cholecystitis
Interventions
TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia, TIVA - Tachycardia, INH - Hypotension, INH - Hypertension, INH - Bradycardia, INH - Tachycardia
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue

NCT00775294
View directory record Official record
Conditions
HIV/AIDS
Interventions
Maraviroc
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of AV-380 in Healthy Subjects

NCT04815551
View directory record Official record
Conditions
Cachexia
Interventions
AV-380, Placebo
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 20, 2026, 10:04 PM EDT
Recruiting Not applicable Interventional

Initial Resuscitation for Acute Kidney Injury in Cirrhosis

NCT06525623
View directory record Official record
Conditions
Cirrhosis, Liver, Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Recommendation: No Further Resuscitation, Recommendation: Resuscitation with Crystalloid, Recommendation: Resuscitation with Colloid, Recommendation: Standard of Care IV Albumin
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 20, 2026, 10:04 PM EDT